国产贝达奎林联合化疗方案治疗耐多药结核病的成本-效果分析*

IF 3 3区医学 Q2 ENVIRONMENTAL SCIENCES

Biomedical and Environmental Sciences Pub Date : 2023-06-01 DOI:10.3967/bes2023.061

XU Cai Hong , QIU Ying Peng , HE Zi Long , HU Dong Mei , YUE Xiao , CHEN Zhong Dan , XU Yuan Yuan , ZHAO Yan Lin

{"title":"国产贝达奎林联合化疗方案治疗耐多药结核病的成本-效果分析*","authors":"XU Cai Hong , QIU Ying Peng , HE Zi Long , HU Dong Mei , YUE Xiao , CHEN Zhong Dan , XU Yuan Yuan , ZHAO Yan Lin","doi":"10.3967/bes2023.061","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>This study aims to estimate the cost-effectiveness of the combined chemotherapy regimen containing Bedaquiline (BR) and the conventional treatment regimen (CR, not containing Bedaquiline) for the treatment of adults with multidrug-resistant tuberculosis (MDR-TB) in China.</p></div><div><h3>Methods</h3><p>A combination of a decision tree and a Markov model was developed to estimate the cost and effects of MDR patients in BR and CR within ten years. The model parameter data were synthesized from the literature, the national TB surveillance information system, and consultation with experts. The incremental cost-effectiveness ratio (ICER) of BR <em>vs</em>. CR was determined.</p></div><div><h3>Results</h3><p>BR (<em>vs</em>. CR) had a higher sputum culture conversion rate and cure rate and prevented many premature deaths (decreased by 12.8%), thereby obtaining more quality-adjusted life years (QALYs) (increased by 2.31 years). The per capita cost in BR was as high as 138,000 yuan, roughly double that of CR. The ICER for BR was 33,700 yuan/QALY, which was lower than China’s 1× per capita Gross Domestic Product (GDP) in 2020 (72,400 yuan).</p></div><div><h3>Conclusion</h3><p>BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.</p></div>","PeriodicalId":55364,"journal":{"name":"Biomedical and Environmental Sciences","volume":"36 6","pages":"Pages 501-509"},"PeriodicalIF":3.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China*\",\"authors\":\"XU Cai Hong , QIU Ying Peng , HE Zi Long , HU Dong Mei , YUE Xiao , CHEN Zhong Dan , XU Yuan Yuan , ZHAO Yan Lin\",\"doi\":\"10.3967/bes2023.061\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>This study aims to estimate the cost-effectiveness of the combined chemotherapy regimen containing Bedaquiline (BR) and the conventional treatment regimen (CR, not containing Bedaquiline) for the treatment of adults with multidrug-resistant tuberculosis (MDR-TB) in China.</p></div><div><h3>Methods</h3><p>A combination of a decision tree and a Markov model was developed to estimate the cost and effects of MDR patients in BR and CR within ten years. The model parameter data were synthesized from the literature, the national TB surveillance information system, and consultation with experts. The incremental cost-effectiveness ratio (ICER) of BR <em>vs</em>. CR was determined.</p></div><div><h3>Results</h3><p>BR (<em>vs</em>. CR) had a higher sputum culture conversion rate and cure rate and prevented many premature deaths (decreased by 12.8%), thereby obtaining more quality-adjusted life years (QALYs) (increased by 2.31 years). The per capita cost in BR was as high as 138,000 yuan, roughly double that of CR. The ICER for BR was 33,700 yuan/QALY, which was lower than China’s 1× per capita Gross Domestic Product (GDP) in 2020 (72,400 yuan).</p></div><div><h3>Conclusion</h3><p>BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.</p></div>\",\"PeriodicalId\":55364,\"journal\":{\"name\":\"Biomedical and Environmental Sciences\",\"volume\":\"36 6\",\"pages\":\"Pages 501-509\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedical and Environmental Sciences\",\"FirstCategoryId\":\"1089\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0895398823000843\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENVIRONMENTAL SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical and Environmental Sciences","FirstCategoryId":"1089","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0895398823000843","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENVIRONMENTAL SCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

目的本研究旨在评估含贝达奎林（BR）和常规治疗方案（CR，不含贝达奎林）联合化疗方案治疗中国成人耐多药结核病（MDR-TB）的成本效益BR和CR患者在10年内。模型参数数据来自文献、国家结核病监测信息系统和专家咨询。测定BR与CR的增量成本效益比（ICER）。结果BR（与CR相比）具有更高的痰培养转化率和治愈率，并预防了许多过早死亡（减少了12.8%），从而获得了更多的质量调整生命年（增加了2.31年）。BR的人均成本高达13.8万元，大约是CR的两倍。BR的ICER为3.37万元/QALY，低于中国2020年的1×人均国内生产总值（GDP）（7.24万元）。结论BR具有成本效益。当Bedaquiline的单价达到或低于57.21元/台时，BR有望成为中国市场上优于CR的主导策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China*

Objective

This study aims to estimate the cost-effectiveness of the combined chemotherapy regimen containing Bedaquiline (BR) and the conventional treatment regimen (CR, not containing Bedaquiline) for the treatment of adults with multidrug-resistant tuberculosis (MDR-TB) in China.

Methods

A combination of a decision tree and a Markov model was developed to estimate the cost and effects of MDR patients in BR and CR within ten years. The model parameter data were synthesized from the literature, the national TB surveillance information system, and consultation with experts. The incremental cost-effectiveness ratio (ICER) of BR vs. CR was determined.

Results

BR (vs. CR) had a higher sputum culture conversion rate and cure rate and prevented many premature deaths (decreased by 12.8%), thereby obtaining more quality-adjusted life years (QALYs) (increased by 2.31 years). The per capita cost in BR was as high as 138,000 yuan, roughly double that of CR. The ICER for BR was 33,700 yuan/QALY, which was lower than China’s 1× per capita Gross Domestic Product (GDP) in 2020 (72,400 yuan).

Conclusion

BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biomedical and Environmental Sciences 环境科学-公共卫生、环境卫生与职业卫生

CiteScore

2.60

自引率

8.60%

发文量

2170

审稿时长

1.0 months

期刊介绍： Biomedical and Environmental Sciences (BES) is a peer-reviewed journal jointly established by the Chinese Center for Disease Control and Prevention (China CDC) and the Coulston International Corporation (CIC), USA in 1988, and is published monthly by Elsevier. It is indexed by SCI, PubMed, and CA. Topics covered by BES include infectious disease prevention, chronic and non-communicable disease prevention, disease control based on preventive medicine, and public health theories. It also focuses on the health impacts of environmental factors in people''s daily lives and work, including air quality, occupational hazards, and radiation hazards. Article types considered for publication include original articles, letters to the editor, reviews, research highlights, and policy forum.